PTN - awaiting phase III clinical trials

Will see what the stock does over the next few days.  It is a superior drug to the one VRX bought from Sprout for $1B.  Works better and also has no side effects, current labelling for Addyi has major restrictions.  That was an approved drug and this is just great phase III data but the market for this drug is really, really big.  Just like Viagra.  Who really knows how these things work out though.